Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

Financial Statements

  Year Ending Dec 2017 (Update) Year Ending Dec 2016 (Update) Year Ending Dec 2015 (Update) Year Ending Dec 2014 (Update)
Net Income/Starting Line -91.25 -68.51 -50.79 -45.72
Depreciation – Supplemental 27.97 26.49 31.87 25.35
Depreciation/Depletion 27.97 26.49 31.87 25.35
Deferred Taxes -5.24 -0.10 0.21 1.12
Unusual Items -9.65 -2.22 7.16 --
Other Non-Cash Items 25.94 20.38 17.16 29.98
Non-Cash Items 16.29 18.16 24.32 29.98
Accounts Receivable 7.69 -9.49 40.25 -21.67
Inventories 4.32 -5.80 1.86 4.25
Prepaid Expenses -6.14 -0.42 -0.45 -0.72
Other Assets 5.24 4.85 -8.75 -11.09
Accrued Expenses -0.46 -0.77 -1.33 -0.36
Payable/Accrued 5.52 -4.03 -28.30 5.30
Other Liabilities -2.80 -0.83 -2.16 9.93
Other Operating Cash Flow
Changes in Working Capital 13.37 -16.50 1.13 -14.36
Cash from Operating Activities -38.86 -40.46 6.74 -3.63
Purchase of Fixed Assets -0.47 -0.08 -0.22 -0.93
Purchase/Acquisition of Intangibles --
Capital Expenditures -0.47 -0.08 -0.22 -0.93
Acquisition of Business --
Sale/Maturity of Investment -- -- 3.06 4.09
Investment, Net -0.02
Purchase of Investments --
Intangible, Net --
Other Investing Cash Flow -0.60 -0.60 -- -25.00
Other Investing Cash Flow Items, Total -0.62 -0.60 3.06 -20.91
Cash from Investing Activities -1.08 -0.68 2.84 -21.84
Other Financing Cash Flow 32.98 -4.35 -- --
Financing Cash Flow Items 32.98 -4.35 -- --
Cash Dividends Paid - Preferred -- -0.01
Total Cash Dividends Paid -- -0.01 --
Sale/Issuance of Common 129.28 74.54 0.63 0.64
Repurchase/Retirement of Common -4.33 -1.40 -0.64 -1.73
Common Stock, Net 124.95 73.14 -0.01 -1.09
Options Exercised 5.48 0.20 1.48 1.91
Warrants Converted -27.19 -0.33 --
Issuance (Retirement) of Stock, Net 103.24 73.01 1.47 0.81
Long Term Debt Issued -- --
Long Term Debt Reduction -- --
Long Term Debt, Net -27.50 -9.01 -- --
Issuance (Retirement) of Debt, Net -27.50 -9.01 -- --
Cash from Financing Activities 108.72 59.64 1.47 0.81
Foreign Exchange Effects 0.32 -0.03 -1.25 -1.71
Net Change in Cash 69.10 18.48 9.80 -26.36
Net Cash - Beginning Balance 158.22 139.74 129.94 156.31
Net Cash - Ending Balance 227.32 158.22 139.74 129.94
Cash Interest Paid 2.69 3.30 3.30 3.23
Cash Taxes Paid 0.02 0.01 0.34 0.33

In millions of USD (except for per share items)

Back to top

Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

Copyright Nasdaq. Minimum 15 minutes delayed.